Equities research analysts at Lazard Capital Markets upped their price target on shares of Gilead Sciences (NASDAQ: GILD) to $58.00 in a research note issued to investors on Wednesday.
GILD has been the subject of a number of other recent research reports. Analysts at Piper Jaffray raised their price target on shares of Gilead Sciences to $50.00 in a research note to investors on Tuesday. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Gilead Sciences in a research note to investors on Friday, March 1st. Finally, analysts at RBC Capital raised their price target on shares of Gilead Sciences from $44.00 to $50.00 in a research note to investors on Thursday, February 28th. They now have an “outperform” rating on the stock.
Twenty-one investment analysts have rated the stock with a buy rating, three have assigned an overweight rating, and six have given a hold rating to the company. The company has an average rating of “overweight” and an average price target of $47.50.
Shares of Gilead Sciences traded up 0.10% during mid-day trading on Wednesday, hitting $45.065. Gilead Sciences has a one year low of $22.40 and a one year high of $45.58. The stock’s 50-day moving average is currently $40.82. The company has a market cap of $68.461 billion and a P/E ratio of 27.45.
Gilead Sciences last issued its quarterly earnings data on Monday, February 4th. The company reported $0.50 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.48 by $0.02. The company had revenue of $2.59 billion for the quarter, compared to the consensus estimate of $2.43 billion. During the same quarter last year, the company posted $0.97 earnings per share. Gilead Sciences’s revenue was up 17.6% compared to the same quarter last year. On average, analysts predict that Gilead Sciences will post $2.02 earnings per share for the current fiscal year.
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
